An NCI-designated Comprehensive Cancer Center
Linda Chan

Lai (Linda) Chan, Ph.D.

Assistant Research Professor, Department of Systems Biology
Research Focus
  • Investigate the role of kinases, phosphatases and transcription factors in regulating oncogenic signaling and metabolism for the development of cancer therapeutics
  • Understand the role of the transcriptional repressor and proto-oncogene BCL6 in Philadelphia-negative acute lymphoblastic leukemia
Email: [email protected]
Lai (Linda) Chan, Ph.D., is an assistant research professor in the Department of Systems Biology at Beckman Research Institute of City of Hope.
Dr. Chan earned her B.S. in biochemistry and chemistry at the University of Illinois at Urbana-Champaign, and a Ph.D. in molecular biology at UCLA. As a graduate student working with Fuyuhiko Tamanoi, Ph.D., she performed a chemical biology study to develop small molecule inhibitors of geranylgeranyltransferase-I (GGTIs).  Furthermore, she investigated the molecular mechanisms and targets of GGTIs in human pancreatic and lung cancer cell lines. 
As a postdoctoral scientist with Markus Müschen, M.D., Ph.D., at the University of California, San Francisco, she discovered that B-cell transcription factors (PAX5, IKZF1) protect B cell precursors from malignant transformation by restricting glucose and energy supply. The goal of Dr. Chan’s research is to elucidate the role of kinases, phosphatases, and transcription factors in regulating oncogenic signaling and metabolism for the development of cancer therapeutics.
  • Chan LN, Müschen M. B-cell identity as a metabolic barrier against malignant transformation. Exp Hematol. 2017 Sep;53:1-6. doi: 10.1016/j.exphem.2017.06.004. Epub 2017 Jun 24.
  • Chan LN, Chen Z, Braas D, Lee JW, Xiao G, Geng H, Cosgun KN, Hurtz C, Shojaee S, Cazzaniga V, Schjerven H, Ernst T, Hochhaus Z, Kornblau SM, Konopleva M, Pufall MA, Cazzaniga G, Liu GJ, Milne TA, Koeffler HP, Ross TS, Sánchez-García I, Borkhardt A, Yamamoto KR, Dickins RA, Graeber TG, and Müschen M. Metabolic gatekeeper function of B-lymphoid transcription factors. Nature (2017) 542 (7642): 479-483.
  • Shojaee S, Chan LN, Buchner M, Cazzaniga V, Cosgun KN, Geng H, Qiu YH, von Minden MD, Ernst T, Hochhaus A, Cazzaniga G, Melnick A, Kornblau SM, Graeber TG, Wu H, Jumaa H and Müschen M. PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nature Medicine. (2016) 22(4): 379-387.
  • Shojaee S, Caeser R, Buchner M, Park E, Swaminathan S, Hurtz C, Geng H, Chan LN, Klemm L, Hofmann WK, Qiu YH, Zhang N, Coombes KR, Paietta E, Molkentin J, Koeffler HP, Willman CL, Hunger SP, Melnick A, Kornblau SM and Müschen M. Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. Cancer Cell (2015) 28(1):114-128.
  • Geng H, Hurtz C, Lenz KB, Chen Z, Baumjohann D, Thompson S, Goloviznina NA, Chen WY, Huan J, LaTocha D, Ballabio E, Xiao G, Lee JW, Deucher A, Qi Z, Park E, Huang C, Nahar R, Kweon SM, Shojaee S, Chan LN, Yu J, Kornblau SM, Bijl JJ, Ye BH, Mark Ansel K, Paietta E, Melnick A, Hunger SP, Kurre P, Tyner JW, Loh ML, Roeder RG, Druker BJ, Burger JA, Milne TA, Chang BH and Müschen M. Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell (2015) 27(3):409-425.
  • Kharabi Masouleh B, Geng H, Hurtz C, Chan LN, Logan AC, Chang MS, Huang C, Swaminathan S, Sun H, Paietta E, Melnick AM, Koeffler P and Müschen M. Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA (2014) 111(21):E2219-2228.
  • Zimonjic DB, Chan LN, Tripathi V, Lu J, Kwon O, Popescu NC, Lowy DR and Tamanoi F. In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells. BMC Cancer (2013) 13:198.
  • Ramezani-Rad P, Geng H, Chen Z, Chan LN, Jumaa H, Melnick A, Paietta E, Carroll WL, Willman CL, Lefebvre V and Müschen M. SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia. Blood (2013) 121(1):148-155.
  • Chan LN, Fiji HDG, Watanabe M, Kwon O and Tamanoi F. Identification and characterization of mechanism of action of P61-E7, a novel phosphine catalysis-based inhibitor of geranylgeranyltransferase-I. PLoS One (2011) 6(10):e26135.
  • Chan LN*, Hart C*, Guo L, Nyberg T, Davies BSJ, Fong LG, Young SG, Agnew BJ and Tamanoi F. A novel approach to tag and identify geranylgeranylated proteins. Electrophoresis 30 (2009) 3598-3606. *These authors contributed equally to this work.
  • Lu J, Chan L, Fiji HD, Dahl R, Kwon O and Tamanoi F. In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase I. Mol. Cancer Ther. 8 (2009) 1218-26.
  • Watanabe M, Fiji HD, Guo L, Chan L, Kinderman SS, Slamon DJ, Kwon O and Tamanoi F. Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds. J Biol. Chem. 283 (2008) 9571-9579.
  • Ghiani CA, Stacevic M, Rodriguez-Fernandez I, Nazarian R, Cheli VT, Chan LN, Malvar JS, de Vellis J, Sabatti C and Dell’Angelica EC. The dysbindin-containing complex (BLOC-1) in brain: developmental regulation, interaction with SNARE proteins, and role in neurite outgrowth. Mol. Psychiatry 15 (2010) 204-15.
  • Perrault WR, Pearlman BA, Godrej DB, Jeganathan A, Yamagata K, Chen JJ, Lu CV, Herrinton PM, Gadwood RC, Chan L, Lyster MA, Maloney MT, Moeslein JA, Greene ML and Barbachyn MR. The synthesis of N-Aryl-5(S)-aminomethyl-2-oxazolidinone antibacterials and derivatives in one step from Aryl Carbamates. Org. Process Res. Dev. 7 (2003) 533-546.
In The News
An Expert's Voice
breakthroughs - cancer cells

Researchers discover sugar-addiction of cancer cells in childhood leukemia